NCT03275870View on ClinicalTrials.gov

Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Hidradenitis SuppurativaHidradenitisAcne InversaBoilsFollicular Occlusion TriadFollicular Occlusion Tetrad
Interventions
DRUG

Hydroxychloroquine

Treatment of patients with hidradenitis suppurativa with hydroxychloroquine 200mg BID for 6 months

Trial Locations (1)

15213

University of Pittsburgh, Pittsburgh

All Listed Sponsors
collaborator

University of Pittsburgh

OTHER

lead

Elena Gonzalez Brant, MD

OTHER

NCT03275870 - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter